Iron overload and unique susceptibility of liver transplant recipients to disseminated disease due to opportunistic pathogens

Liver Transplantation

Volumn 14, Issue 9, 2008, Pages 1249-1255

  Singh, Nina ^a,c   Sun, Hsin Yun ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; DEFEROXAMINE; FERROPORTIN; GAMMA INTERFERON; HEPCIDIN; IRON BINDING PROTEIN; RAPAMYCIN;

ADAPTIVE IMMUNITY; ASPERGILLOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; GRAFT RECIPIENT; HIGH RISK PATIENT; HOST RESISTANCE; HUMAN; INNATE IMMUNITY; IRON OVERLOAD; LIVER TRANSPLANTATION; MOLECULAR MECHANICS; MUCORMYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS;

ASPERGILLOSIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; CYTOMEGALOVIRUS; HEPACIVIRUS; HOMEOSTASIS; HUMANS; IRON; IRON OVERLOAD; LIVER TRANSPLANTATION; OPPORTUNISTIC INFECTIONS; SIMPLEXVIRUS; STAPHYLOCOCCUS AUREUS; T-LYMPHOCYTES, HELPER-INDUCER; ZYGOMYCOSIS;

EID: 51349152242     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21587     Document Type: Review

References (95)

1. Fung J, Kelly D, Kadry Z, Patel-Tom K, Eghtsad B. Immunosuppression in liver transplantation: beyond calcineurin inhibitors. Liver Transpl 2005;11:267-280.
2. Post DJ, Douglas DD, Mulligan DC. Immunosuppression in liver transplantation. Liver Transpl 2005;11:1307-1314.
3. Kusne S, Dummer JS, Singh N, Iwatsuki S, Makowka L, Esquivel C, et al. Infections after liver transplantation, an analysis of 101 consecutive cases. Medicine 1988;67:132-143.
4. Singh N. Infectious diseases in the liver transplant recipient. Semin Gastrointest Dis 1998;9:136-146.
5. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005;18:44-69.
6. Gavalda J, Len O, San Juan R, Aguado J, Fortun J, Lumbreras C, et al., for RESITRA (Spanish Network for Research on Infection in Transplantation). Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005;41:52-59.
7. Paya CV. Fungal infections in solid-organ transplarration. Clin Infect Dis 1993;16:677-688.
8. George DL, Arnow PM, Fox AS, Baker AL, Thistlewaite JR, Emond JC, et al. Bacterial infection as a complication of liver transplantation: epidemiology and risk factors. Rev Infect Dis 1991;13:387-396.
9. Colonna JO, Winston DJ, Brill JE, Goldstein LI, Hoff MP, Hiatt JR, et al. Infectious complications in liver transplantation. Arch Surg 1988;12:360-364.
10. Singh N, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007;195:756-764.
11. Almyroudis N, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006;6:2365-2374.
12. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al., for the Valganciclovir and Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611-620.
13. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Infections due to methicillin-resistant S. aureus: the other emerging resistant gram-positive coccus in liver transplant recipients. Clin Infect Dis 2000;30:322-327.
14. Boon AP, O'Brien D, Adams DH. 10 year review of invasive aspergillosis detected at necropsy. J Clin Pathol 1992; 452-455.
15. Husain C, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001;7:375-381.
16. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine 1999;78:123-138.
17. Mehrad B, Paciocco G, Martinez FJ, et al. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest 2001;119:169-175.
18. Husain S, Kwak EJ, Obman A, Wagener MM, Kusne S, Stout J, et al. Prospective assessment of Platelia Aspergillus galactomannan for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004; 4:796-802.
19. Kanj SS, Sharara AI, Clavien PA, Hamilton JD. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 1996;22:537-549.
20. Forrest GN, Mankes K. Outcomes of invasive zygomycosis infections in renal transplant recipients. Transplant Infect Dis 2007;9:161-164.
21. Aslani J, Eizadi M, Kardavani B, Khoddami-Vishteh HR, Nemati E, Hoseini SM, Einollahi B. Mycormycosis after kidney transplantations: report of seven cases. Scand J Infect Dis 2007;39:703-706.
22. Davari HR, Malekhkossini SA, Salahi H, Bahador A, Saberifirozi M, Geramizadeh B, et al. Outcome of mucormycosts in liver transplantation: four cases and a review of literature. Exp Clin Transplant 2003;1:147-152.
23. Schneider CR, Buell JF, Thomas GM, Hanaway MJ, Rudich SM, Woodle ES. Methicillin-resistant Staphylococcus aureus infection in liver transplantation: a matched controlled study. Transplant Proc 2005;37:1243-1244.
24. Torre-Cisneros J, Herrero C, Canas E, Reguera JM, De La Mata M, Gomez-Bravo MA. High mortality related with Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 2002;21:385-388.
25. Bert F, Bellier C, Lassel L, Lefranc V, Durand F, Belghiti J, et al. Risk factors for Staphylococcus aureus infection in liver transplant recipients. Liver Transpl 2005;11:1093-1099.
26. Chang FY, Singh N, Gayowski T, Drenning SD, Wagener MM, Mariono JR. Staphylococcus aureus nasal colonization and association with infections in liver transplant recipients. Transplantation 1998;65:1169-1172.
27. Singh N, Paterson DL, Chang FY, Gayowski T, Squier C, Wagener MM, Marino IR. Methicillin-resistant Staphlococcus aureus: the other emerging resistant Gram-positive coccus among liver transplant recipients. Clin Infect Dis 2000;30:322-327.
28. Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, et al. Does Valganciclovir hydrochloride (Valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transplant Proc 2005; 37:3182-3186.
29. Limaye AP, Bakthavatsalam R, Kim HW, Kuhr CS, Halldorson JB, Healey PJ, Boeckh M. Late-onset CMV disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004;78:9-16.
30. Kusne S, Schwartz M, Breinig MK, Durnmer JS, Lee RE, Selby R, et al. Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis 1991;163: 1001-1007.
31. Peters AJ, Hanto BE, Herpes viral hepatitis in liver transplant recipients. Herpes viral hepatitis in liver transplant recipients. Clin Transplant 1992:6:16-20.
32. Tung BY, Farrell FJ, McCashland TM, Gish RG, Bacon BR, Keeffe EB, Kowdley KV. Long-term follow-up after liver transplantation in patients with hepatic iron overload. Liver Transpl 1999;5:369-374.
33. Keeffe EB. Liver transplantation in patients with hepatic iron overload: favorable or unfavorable outcome? Hepatology 2000;32:1396-1398.
34. Singh N, Warmstedt C, Keyes L, Mayher D, Tickerhoof L, Akoad M, et al. Hepatic iron content and the risk of Staphylococcus aureus bacteremia. in liver transplant recipients. Prog Transplant 2007;17:1-5.
35. Deugnier Y, Brissot P, Loréal O. Iron and the liver: update 2008. J Hepatol 2008:10:1016.
36. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276:7819.
37. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806-7810.
38. Bekri S, Gual P, Anty R, Luciani N, Dahman M, Ramesh B. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterol 2006;131:788-796.
39. Peyssonnaux C, Zinkernagel AS, Datta V, Lauth X, Johnson RS, Nizet V. TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood 2006;107:3732.
40. Detivaud L, Nemeth E, Boudjema K, Turlin B, Troadec MB, Leroyer P. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood 2005;106:746-748.
41. Duane P, Raja KB, Simpson RJ, Peters TJ. Intestinal iron absorption in chronic alcoholics. Alcohol 1992;27:539-544.
42. Alexander J, Limaye AP, Ko CW, Bronner MP, Kowdley KV. Association of hepatic iron overload with invasive fungal infection in liver transplant recipients. Liver Transpl 2006; 12:1799-1804.
43. Schrettl M, Bignell E, Kragl C, Joechl C, Rogers T, Arst H, et al. Siderophore biosynthesis but not reductive iron assimilation is essential for Aspergillus fumigatus virulence. J Infect Dis 2004;200:1213-1219.
44. Boelaret JR, Daneels RF, Schurgers ML, Matthys EG, Gordts BZ, Van Landuyt HW. Iron overload in hemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant 1990;5:130-134.
45. Oexle H, Kaser A, Möst J, Bellmann-Weiler R, Werner ER, Werner-Flemayer G, Weiss G. Pathways for the regulation of interferon-gamma-inducible genes by iron in human monocytic cells. J Leukoc Biol 2003;74:287-294.
46. Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Flemayer G, Wachter H. Iron modulates interferon-gamma effects in the human myelomonocytic cell line THP-1. Exp Hematol 1992;20:605-610.
47. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001;2:907-916.
48. Theurl I, Fritsche G, Ludwiczek S, Garimorth K, Bellmann-Weiler R, Weiss G. The macrophage: a cellular factory at the interphase between iron and immunity for the control of infections. Biometals 2005;18:359-367.
49. van Asbeck BS, Marx JJ, Struyvenberg A, van Kats JH, Verhoef J. Effect of iron (III) in the presence of various ligands on the phagocytic and metabolic activity of human polymorphonuclear leukocytes. J Immunol 1984;132:851-856.
50. Kontoyiannis D, Chamilos G, Lewis R, Giralt S, Cortes J, Raad I, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologoic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 2007;110:1303-1306.
51. Miceli M, Dong L, Grazziutti ML, Fassas A, Thertulien R, Van Rhee F, et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant 2006;37:857-864.
52. Snydman DR. The potential role for iron overload and fungal infection in liver transplantation. Liver Transpl 2006;12:1731-1732.
53. Brandhagen DJ, Alvarez W, Therneau TM, Kruckeberg KE, Thibodeau SN, Ludwig J, Porayko MK. Iron overload in cirrhosis: HFE genotypes and outcome after liver transplantation. Hepatology 2000;31:456-460.
54. Iglesias-Osma C, Gonzalez-Villaron L, San Miguel J, Caballero MD, Vazuquez L, de Castro S. Iron metabolism and fungal infections in patients with haematological malignancies. J Clin Pathol 1995;48:223-225.
55. Altes A, Remacha A, Sarda P, Sancho F, Sureda A, Martino R, et al. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant 2004;34:505-509.
56. 5-monooxygenase (sidA) and a non-ribosomal peptide synthetase (sidC). Mol Microbiol 2003;49:359-375.
57. 5-oxygenase, is required for virulence. Infect Immun 2005; 73:5493-5503.
58. Hissen A, Chow J, Pinto L, Moore M. Survival of Aspergillus fumigatus in serum involves removal of iron from transferrin: the role of siderophores. Infect Immun 2004; 72:1402-1408.
59. Rementeria A, López-Molina N, Ludwig A, Vivanco A, Bikandi J, Pontón J, Garaizar J. Genes and molecules involved in Aspergillus fumigatus virulence. Rev Iberoam Micol 2005;22:1-23.
60. Abe F, Inaba H, Katoh T, Hotchi M. Effects of iron and desferrrioxamine on Rhizopus infection. Mycopathologia 1990;110:87-91.
61. Van Custem J, Boelaert JR. Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int 1989;36:1061-1068.
62. Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982;31: 1109-1114.
63. Boelaert JR, Van Custem J, de Locht M, Schneider YJ, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int 1994;45:667-671.
64. Boelaert JR, de Locht M, Van Custem J, Kerrels V, Cantinieaux B, Verdonck A, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993;91: 1979-1986.
65. Jung WH, Sham A, White R, Kronstad JW. Iron regulation of the major virulence factors in the AIDS-associated pathogen Cryptococcus neoformans. PloS Biol 2006;4:2282-2295.
66. Jung WH, Kronstad JW. Iron and fungal pathogenesis: a case study with Cryptococcus neoformans. Cell Microbiol 2008;10:277-284.
67. Howard DH. Acquisition, transport, and storage of iron by pathogenic fungi. Clin Microbiol Rev 1999;12:394-404.
68. Kartikasari AE, Georgiou NA, de Geest M, van Kats-Renaud JH, Bouwman JJ, van Asbeck BS, et al. Iron enhances endothelial cell activation in response to Cytomegalovirus or Chlamydia pneumoniae infection. Eur J Clin Invest 2006;36:743-752.
69. Cinatl J Jr, Cinatl J, Rabenau H, Gümbel HO, Kornhuber B, Doerr HW. In vitro inhibition of human cytomegalovirus replication by desferrioxamine. Antiviral Res 1994;25:73-77.
70. Cinatl J, Scholz M, Weber B, Cinatl J, Rabenau H, Markus BH, et al. Effects of desferrioxamine on human cytomegalovirus replication and expression of HLA antigens and adhesion molecules in human vascular endothelial cells. Transpl Immunol 1995;3:313-320.
71. Kakhlon O, Cabantchik ZI. The labile iron pool: characterization, measurement, and participation in cellular processes. Free Radic Biol Med 2002;33:1037-1046.
72. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003;102:2670-2677.
73. Crowe WE, Maglova LM, Ponka P, Russell JM. Human cytomegalovirus-induced host cell enlargement is iron dependent. Am J Physiol Cell Physiol 2004;287:C1023-C1030.
74. Ben-Arieh SV, Zimerman B, Smorodinsky NI, Yaacubovicz M, Schechter C, Bacik I, et al. Human cytomegalovirus protein US2 Interferes with the expression of human HFE, a nonclassical class 1 major histocompatibility complex molecule that regulates iron homeostasis. Virol 2001;75: 10557-10562.
75. Haririan A, Morawski K, West MS, El-Amm JM, Doshi MD, Cincotta E, et al. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients. Clin Transplant 2007;21:466-471.
76. Marty F, Bryar J, Browne S, Schwarzberg T, Ho V, Bassett I, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytornegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2008;110:490-500.
77. Maiorano A, Stallone G, Schena A, Infante B, Pontrelli P, Schena F, Grandaliano G. Sirolimus interferes with iron homeostasis in renal transplant recipients. Transplantation 2006;82:908-912.
78. Skaar EP, Humayun M, Bae T, DeBord KL, Schneewind O. Iron-source preference of Staphylococcus aureus infections. Science 2004;305:1626-1628.
79. Rouault TA. Pathogenic bacteria prefer herne. Science 2004;305:1577-1578.
80. Ammendolia M, Marchetti M, Superti F. Bovine lactoferrin prevents the entry and intercellular spread of herpes simplex virus type 1 in green monkey kidney cells. Antivir Res 2007;76:252-262.
81. Weiss G, Umlauft F, Urbanek M, Herold M, Lovevsky M, Offner F, Gordeuk VR. Associations between cellular immune effector function, iron metabolism, and disease activity in patients with chronic hepatitis C virus infection. J Infect Dis 1999;180:1452-1458.
82. Farigon S, Fracabzani AL, Sampietro M, Molteni V, Boldorini R, Mattioli M, et al. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol 1997;9:497-503.
83. Piperno A, Sampietro M, D'Alba R, Roffi L, Fargion S, Parma S, et al. Iron stores, response to alpha interferon therapy and effects of iron depletion in chronic hepatitis C. Liver 1996;16:248-254.
84. Walker EMJ, Walker SM. Effects of iron overload on the immune system. Ann Clin Lab Sci 2000;30:354-365.
85. Schaible U, Kaufmann S. Iron and microbial infection. Nat Rev 2004;4:946-953.
86. Recalcati S, Pometta R, Levi S, Conte D, Cairo G. Response of monocyte iron regulatory protein activity to inflammation: abnormal behavior in genetic hemochromatosis. Blood 1998;91:2565-2572.
87. Zhang Y, Crichton RR, Boelaert JR, Jorens PG, Herman AG, Ward RJ, et al. Decreased release of nitric oxide (NO) by alveolar macrophages after in vivo loading of rats with either iron or ethanol. Biochem Pharmacol 1998;55:21-25.
88. Patruta SI, Edlinger R, Sunder-Plassmann G, Hörl WH. Neutorphil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998;9:655-663.
89. Alford CE, King TEJ, Campbell PA. Role of transferrin, transferrin receptors, and iron in macrophage listericidal activity. J Exp Med 1991;174:459-466.
90. Omara FO, Blakley BR. The effects of iron deficiency and iron overload on cell-mediated immunity in the mouse. Br J Nutr 1994;72:899-909.
91. Jiang H, Chess L. Regulation of immune responses by T cells. N Engl J Med 2006;354:1166-1176.
92. Parkin J, Cohen B. An overview of the immune system. Lancet 2001;357:1777-1789.
93. Ibrahim AS, Edwards JE, Filler SG. Clinical mycology. In: Dismukes WE, Pappas PG, Sobel JD, editors. Zygomycosis. New York: Oxford University Press; 2003:241-251.
94. Waldorf AR, Levitz S, Diamond RD. In vivo bronchoalveolar macrphage defense against Rhizopus oryzae and Aspergillus fumigatus. J Infect Dis 1984;150:752-760.
95. Waldorf AR. Pulmonary defense mechanisms against opportunistic fungal pathogens. Immunol Ser 1989;47:243-271.